This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Sep 2015

The new age of regenerative medicine: why stem cell therapy?

Frost & Sullivan webinar reveals stem cell therapy pipeline and treatments innovating regenerative medicine.

Cell therapy is the fastest growing segment of regenerative medicine, the majority of which is stem cell therapy. It is estimated the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.

Many factors determine the rate at which the stem cell therapy market advances. It is driven by documented successes and research indicating the potential of stem cell treatments to cure life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world’s ageing populations.

In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20% of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes and industry regulation changes.

The analyst briefing will explore successful stem cell therapy treatments and marketed products within the industry. It will consider the stem cell therapy pipeline including phases of clinical trials and leading indications, in addition to manufacturing considerations.

Attend this webinar to discover tangible insights on

  • The stem cell therapy market, including its size and projected growth
  • The current state and future trends of the industry
  • Funding and partnerships within the stem cell therapy market
  • Centers of excellence and venture capital.

    This presentation is directed towards strategy specialists and service providers, as well as investor groups looking for emerging opportunities within the segment of regenerative medicine.

    “Stem cell therapy is a new and rapidly growing industry showing phenomenal potential in its ability to be operated alone or in combination with gene and immunotherapy to cure diseases,” said Frost & Sullivan’s Transformational Health Senior Consultant, Jane Andrews. “A key barrier to market growth is manufacturing, aside from regulatory concerns, it is difficult to efficiently scale up production. The cost of goods sold for autologous production is very high and practical quality process engineering is badly needed for both autologous and allogeneic production to increase profit margins to acceptable levels.”

    To attend the briefing, email Anna Zanchi, Corporate Communications ([email protected]) your full name, job title, company name, company telephone number, and company email address, website, city and country.

  • Related News